Back to News
Market Impact: 0.2
BioVie's Bezisterim Shows Positive Signals In Long COVID Patients With Greater Symptom Burden
Source: Nasdaq
Healthcare & Biotech
BioVie Inc. announced that it presented Phase 2 data on investigational bezisterim (NE3107) for Long COVID at the 151st Annual Meeting of the American Neurological Association. The available article text does not report the data results or their implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
BIVI0.35
More News
- BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroups
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What a Concept From Nature Tells Us About How C-Suite Executives Actually Think About AI
- How to Track Earnings Call Sentiment Across Companies